[go: up one dir, main page]

AR114077A1 - Polipéptidos de unión al receptor de transferrina y usos de los mismos - Google Patents

Polipéptidos de unión al receptor de transferrina y usos de los mismos

Info

Publication number
AR114077A1
AR114077A1 ARP190100045A ARP190100045A AR114077A1 AR 114077 A1 AR114077 A1 AR 114077A1 AR P190100045 A ARP190100045 A AR P190100045A AR P190100045 A ARP190100045 A AR P190100045A AR 114077 A1 AR114077 A1 AR 114077A1
Authority
AR
Argentina
Prior art keywords
binding
tfr
fcgr
transferrin receptor
same
Prior art date
Application number
ARP190100045A
Other languages
English (en)
Inventor
Joy Yu Zuchero
Zachary K Sweeney
Adam P Silverman
Wanda Kwan
Mihalis Kariolis
Mark S Dennis
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of AR114077A1 publication Critical patent/AR114077A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se relaciona, en términos generales, con dímeros de polipéptidos Fc que contienen un sitio de unión al receptor de transferrina no natural (TfR), que no disminuyen considerablemente los reticulocitos in vivo, pero que conservan la unión al receptor de Fcg (FcgR). La presente descripción se relaciona también con un dímero de polipéptidos Fc que contiene un sitio no natural que se une específicamente a TfR en uno de los polipéptidos Fc; una modificación o modificaciones en el polipéptido Fc que contiene el sitio de unión a TfR que reduce la unión a FcgR cuando se une a TfR, donde el otro polipéptido Fc no contiene un sitio de unión a TfR pero conserva la unión a FcgR.
ARP190100045A 2018-01-10 2019-01-10 Polipéptidos de unión al receptor de transferrina y usos de los mismos AR114077A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862615914P 2018-01-10 2018-01-10
US201862631281P 2018-02-15 2018-02-15
US201862682639P 2018-06-08 2018-06-08
US201862721275P 2018-08-22 2018-08-22

Publications (1)

Publication Number Publication Date
AR114077A1 true AR114077A1 (es) 2020-07-15

Family

ID=65441044

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190100045A AR114077A1 (es) 2018-01-10 2019-01-10 Polipéptidos de unión al receptor de transferrina y usos de los mismos

Country Status (15)

Country Link
US (1) US20210130485A1 (es)
EP (1) EP3737701A1 (es)
JP (3) JP2021510162A (es)
KR (1) KR102720600B1 (es)
CN (1) CN111741977A (es)
AR (1) AR114077A1 (es)
AU (1) AU2019207735A1 (es)
BR (1) BR112020013921A2 (es)
CA (1) CA3088157A1 (es)
CO (1) CO2020009827A2 (es)
IL (1) IL275969A (es)
MX (1) MX2020007389A (es)
SG (1) SG11202006420TA (es)
TW (1) TW201934573A (es)
WO (1) WO2019140050A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE060983T2 (hu) 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
BR112021002730A2 (pt) * 2018-08-16 2021-08-10 Denali Therapeutics Inc. proteínas bispecíficas engenheiradas
WO2020172457A1 (en) 2019-02-20 2020-08-27 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
PH12022551598A1 (en) 2019-12-23 2023-11-20 Denali Therapeutics Inc Progranulin variants
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
IL308004A (en) * 2021-05-05 2023-12-01 Univ Tennessee Res Found Peptide-fc fusions for treating amyloid disorders
IL309346A (en) * 2021-07-01 2024-02-01 Denali Therapeutics Inc Transferrin receptor-targeted oligonucleotide conjugates
CN115873127A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
EP4448563A1 (en) * 2021-12-17 2024-10-23 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
CN119497720A (zh) * 2022-07-01 2025-02-21 戴纳立制药公司 将寡核苷酸递送至细胞的转铁蛋白受体结合分子缀合物
CN120112164A (zh) 2022-07-29 2025-06-06 瑞泽恩制药公司 包含修饰的转铁蛋白受体基因座的非人动物
IL318625A (en) 2022-07-29 2025-03-01 Regeneron Pharma Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle
EP4562041A2 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Anti-tfr:payload fusions and methods of use thereof
IL318636A (en) 2022-07-29 2025-03-01 Regeneron Pharma Viral particles retargeted to transferrin receptor 1
WO2024130116A2 (en) * 2022-12-16 2024-06-20 Denali Therapeutics Inc. Methods and compositions related to engineered transferrin receptor‑binding molecules
WO2024206161A1 (en) 2023-03-24 2024-10-03 Denali Therapeutics Inc. Abeta-targeting proteins and methods of use
US20250041455A1 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
AR133384A1 (es) 2023-07-28 2025-09-24 Regeneron Pharma Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981217A (en) * 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
ATE441663T1 (de) * 2000-09-06 2009-09-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
EP1545595B1 (en) * 2002-08-30 2010-07-07 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
EP2368578A1 (en) * 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CN101511868B (zh) * 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
KR102031317B1 (ko) * 2012-05-21 2019-10-14 제넨테크, 인크. 혈액-뇌 장벽 수송의 안전성을 개선하는 방법
IL242088B2 (en) * 2013-05-20 2023-12-01 Genentech Inc Anti-transferrin receptor antibodies and methods of use
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
JP6779876B2 (ja) * 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
CN114409783B (zh) * 2015-06-24 2025-09-16 Jcr制药股份有限公司 通过血脑屏障的抗人转铁蛋白受体抗体
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
HUE060983T2 (hu) * 2017-02-17 2023-05-28 Denali Therapeutics Inc Mesterségesen elõállított transferrin receptort kötõ polipeptidek
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
MX2019009817A (es) * 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
CA3061235A1 (en) * 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP3737701A1 (en) 2020-11-18
IL275969A (en) 2020-08-31
TW201934573A (zh) 2019-09-01
JP2024016195A (ja) 2024-02-06
SG11202006420TA (en) 2020-08-28
BR112020013921A2 (pt) 2020-12-01
MX2020007389A (es) 2020-10-14
CA3088157A1 (en) 2019-07-18
WO2019140050A1 (en) 2019-07-18
CO2020009827A2 (es) 2020-10-30
JP2026010691A (ja) 2026-01-22
KR102720600B1 (ko) 2024-10-21
CN111741977A (zh) 2020-10-02
JP2021510162A (ja) 2021-04-15
KR20200119251A (ko) 2020-10-19
AU2019207735A1 (en) 2020-07-23
US20210130485A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
AR114077A1 (es) Polipéptidos de unión al receptor de transferrina y usos de los mismos
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
AR113455A1 (es) Proteínas inmunomoduladoras de variantes del ligando de icos y composiciones y métodos relacionados
CL2017000999A1 (es) Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
CO7170123A2 (es) Complejo del factor viii con xten y proteína del factor von willebrand y sus usos
EA202190906A1 (ru) Рекомбинантное получение препаратов пептидов коллагена и их применение
MX393649B (es) Vacunas y anticuerpos contra el dengue
CO2018013104A2 (es) Polipéptidos de fusión cd40l-fc y sus métodos de uso
MX2018013622A (es) Agentes agonistas de cd47 que inducen muerte celular programada y su uso en los tratamientos de enfermedades asociadas con defectos en la muerte celular programada.
AR102522A1 (es) Variantes de región fc con propiedades modificadas de unión a fcrn y proteína a
MX382848B (es) Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas.
MX2016015868A (es) Metodos y composiciones para el tratamiento de trastornos con polipeptidos de folistatina.
PE20081804A1 (es) Polipeptidos del receptor de activina variante y usos de los mismos
MX387180B (es) Variantes de región fc con propiedades de unión al receptor fc neonatal (fcrn).
WO2014144573A3 (en) Multimerization technologies
DOP2022000150A (es) Anticuerpos multiespecíficos, composiciones que los comprenden, y vectores y usos de los mismos
UA108778C2 (xx) Протираковий злитий протеїн
MX2018000587A (es) Proteinas de fusion de fragmentos de proteina humana para crear composiciones de fc de inmunoglobulina multimerizada de forma ordenada con union al complemento aumentada.
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
EP4249097A3 (en) Fc binding proteins with cysteine in the c-terminal helical region
CO2022000804A2 (es) Proteínas de unión al antígeno anti carcinoma de células escamosas esofágico 1 de nueva york (ny-eso-1) y métodos de uso
BR112021000899A2 (pt) Peptídeos de ligação a il-17a e usos médicos dos mesmos
CL2022001504A1 (es) Anticuerpos anti-glicoproteína ib alfa humanizada (gpibalpha)
AR106981A1 (es) Una composición antimicrobiana

Legal Events

Date Code Title Description
FA Abandonment or withdrawal